Allogene Therapeutics, Inc. (ALLO) |
|
5.02 -0.03 (-0.59%)
|
03-24 16:00 |
|
Open: |
4.99 |
Pre. Close: |
5.05 |
|
High:
|
5.06 |
Low:
|
4.905 |
|
Volume:
|
1,323,310 |
Market Cap:
|
775(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:23:55 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 7.38  One year: 8.4 |
| Support: |
Support1: 4.9 Support2: 4.08 |
| Resistance: |
Resistance1: 6.32 Resistance2: 7.19 |
| Pivot: |
5.54 |
| Moving Average: |
MA(5): 5.16 MA(20): 5.71
MA(100): 7.46 MA(250): 9.66 |
| MACD: |
MACD(12,26): -0.5 Signal(9): -0.5 |
| Stochastic oscillator: |
%K(14,3): 5.3  %D(3): 4.5 |
| RSI: |
RSI(14): 22.5 |
| 52-week: |
High: 17.48 Low: 4.9 |
| Average Vol(K): |
3-Month: 1,910 (K) 10-Days: 1,944 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ALLO ] has closed above bottom band by 9.1%. Bollinger Bands are 41.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.07 - 5.1 |
5.1 - 5.13 |
|
Low:
|
4.82 - 4.86 |
4.86 - 4.89 |
|
Close:
|
4.96 - 5.02 |
5.02 - 5.07 |
|
Company Description |
|
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California. |
Headline News |
Wed, 22 Mar 2023
Bernstein Initiates Coverage of Allogene Therapeutics (ALLO) with ... - Nasdaq
Sun, 19 Mar 2023
Validea's Top Ten Healthcare Stocks Based On Kenneth Fisher - 3 ... - Nasdaq
Sat, 18 Mar 2023
Equities Analysts Issue Forecasts for Allogene Therapeutics, Inc.'s ... - MarketBeat
Fri, 17 Mar 2023
Allogene Therapeutics, Inc. (NASDAQ:ALLO) to Post Q1 2023 ... - MarketBeat
Wed, 15 Mar 2023
Two Sigma Investments LP raises its stake in Allogene Therapeutics ... - Best Stocks
Tue, 14 Mar 2023
Allogene Therapeutics Announces Oral Presentation of Phase 1 ... - Investor Relations | Allogene Therapeutics
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
145 (M) |
|
% Held by Insiders
|
8.359e+007 (%) |
|
% Held by Institutions
|
29.7 (%) |
|
Shares Short
|
34,410 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-3.2115e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-138 |
|
Return on Assets (ttm)
|
44.8 |
|
Return on Equity (ttm)
|
-22.7 |
|
Qtrly Rev. Growth
|
243000 |
|
Gross Profit (p.s.)
|
-9.75 |
|
Sales Per Share
|
-52.55 |
|
EBITDA (p.s.)
|
303750 |
|
Qtrly Earnings Growth
|
-2.3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-221 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-2.3 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.1 |
|
Price to Cash Flow
|
0.87 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
3.686e+007 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
